Assay

Enterome's innovative OncoMimics™-based immunotherapy EO2401 distinguished with 'Best Clinical Research Award' at EANO Meeting 2022 for promising results in recurrent gliobastoma

Retrieved on: 
Friday, September 16, 2022
Neuro, Therapy, Safety, Bevacizumab, Nivolumab, UCP2, IL13RA2, BIRC5, Immunotherapy, Glioblastoma, Patient, FOXM1, Prognosis, Protein, ORR, Sorbonne University, Progression-free survival, Assay, Antigen, Abstract (summary), European Association of Urology, DCR, Association, CD4, PFS, Peptide, AP-HP, Pharmaceutical industry, Vaccine

It combines three OncoMimics peptides that closely mimic IL13Ra2, BIRC5 and FOXM1, which are known driver antigens present on aggressive solid tumors.

Key Points: 
  • It combines three OncoMimics peptides that closely mimic IL13Ra2, BIRC5 and FOXM1, which are known driver antigens present on aggressive solid tumors.
  • At EANO we will be presenting our promising results with a new highly innovative immunotherapy, the OncoMimics-based therapeutic cancer vaccine EO2401 in combination with nivolumab and/or bevacizumab in patients with glioblastoma.
  • EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific effector memory CD8+ T cells, correlating with efficacy.
  • The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in approximately 80 patients at centers in the US and Europe.

Enterome's innovative OncoMimics™-based immunotherapy EO2401 distinguished with 'Best Clinical Research Award' at EANO Meeting 2022 for promising results in recurrent gliobastoma

Retrieved on: 
Friday, September 16, 2022
Neuro, Therapy, Safety, Bevacizumab, Nivolumab, UCP2, IL13RA2, BIRC5, Immunotherapy, Glioblastoma, Patient, FOXM1, Prognosis, Protein, ORR, Sorbonne University, Progression-free survival, Assay, Antigen, Abstract (summary), European Association of Urology, DCR, Association, CD4, PFS, Peptide, AP-HP, Pharmaceutical industry, Vaccine

It combines three OncoMimics peptides that closely mimic IL13Ra2, BIRC5 and FOXM1, which are known driver antigens present on aggressive solid tumors.

Key Points: 
  • It combines three OncoMimics peptides that closely mimic IL13Ra2, BIRC5 and FOXM1, which are known driver antigens present on aggressive solid tumors.
  • At EANO we will be presenting our promising results with a new highly innovative immunotherapy, the OncoMimics-based therapeutic cancer vaccine EO2401 in combination with nivolumab and/or bevacizumab in patients with glioblastoma.
  • EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific effector memory CD8+ T cells, correlating with efficacy.
  • The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in approximately 80 patients at centers in the US and Europe.

Roche's VENTANA PD-L1 (SP263) Assay receives CE IVD approval to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo

Retrieved on: 
Friday, September 9, 2022
Lung cancer, Mortality, Lung, Dow Jones, Regeneron Pharmaceuticals, Cancer, Medication, ALK, View, Large-cell lung carcinoma, Internet, Incidence, Hoffmann-La Roche, Genentech, Phase, Assay, Royal commission, Treatment of lung cancer, Multimedia, RO, PD-1, GlobalData, Medicine, Prevalence, Immunotherapy, News, NSCLC, Pharma, Biomarker, Roche Diagnostics, ROG, Non-small-cell lung carcinoma, CE, PD-L1, European Commission, ROS, Benchmark, Patient, World Health Organization, Medical imaging, Medical device, Uranium, Fine chemical, Cemiplimab, Diagnosis, Chugai Pharmaceutical Co.

This additional approval will allow more patients with locally advanced and metastatic non-small cell lung cancer broader access to the immunotherapy Libtayo.

Key Points: 
  • This additional approval will allow more patients with locally advanced and metastatic non-small cell lung cancer broader access to the immunotherapy Libtayo.
  • This approval gives eligible advanced lung cancer patients access to the immunotherapy Libtayo as a first-line treatment," said Jill German, Head of Pathology Lab at Roche Diagnostics.
  • VENTANA PD-L1 (SP263) Assay is used to detect programmed death ligand-1 (PD-L1) protein in non-small cell lung carcinoma patients.
  • Last month, Roche announced that the VENTANA PD-L1 (SP263) Assay received CE label expansion in non-small cell lung cancer as a companion diagnostic for Tecentriq (atezolizumab).

Roche's VENTANA PD-L1 (SP263) Assay receives CE IVD approval to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo

Retrieved on: 
Friday, September 9, 2022
Lung cancer, Mortality, Lung, Dow Jones, Regeneron Pharmaceuticals, Cancer, Medication, ALK, Large-cell lung carcinoma, Internet, Incidence, Hoffmann-La Roche, Genentech, Phase, Assay, Royal commission, Treatment of lung cancer, RO, PD-1, GlobalData, Medicine, Prevalence, Immunotherapy, News, NSCLC, Pharma, Biomarker, Roche Diagnostics, ROG, Non-small-cell lung carcinoma, CE, PD-L1, European Commission, ROS, Benchmark, Patient, World Health Organization, Medical imaging, Medical device, Uranium, Fine chemical, Cemiplimab, Diagnosis, Chugai Pharmaceutical Co.

This additional approval will allow more patients with locally advanced and metastatic non-small cell lung cancer broader access to the immunotherapy Libtayo.

Key Points: 
  • This additional approval will allow more patients with locally advanced and metastatic non-small cell lung cancer broader access to the immunotherapy Libtayo.
  • This approval gives eligible advanced lung cancer patients access to the immunotherapy Libtayo as a first-line treatment," said Jill German, Head of Pathology Lab at Roche Diagnostics.
  • VENTANA PD-L1 (SP263) Assay is used to detect programmed death ligand-1 (PD-L1) protein in non-small cell lung carcinoma patients.
  • Last month, Roche announced that the VENTANA PD-L1 (SP263) Assay received CE label expansion in non-small cell lung cancer as a companion diagnostic for Tecentriq (atezolizumab).

Enterome to present updates on EO2401, its first-in-class OncoMimics™ therapeutic cancer vaccine targeting solid tumors, at ESMO Congress 2022

Retrieved on: 
Tuesday, September 6, 2022
European Society for Medical Oncology, Glioblastoma, Protein, Associate, Bevacizumab, Peptide, Society, Nivolumab, ESMO, Gustave Roussy, Assay, Antigen, Annual general meeting, Therapy, ASCO, Oncology, MPP, CEST, Adrenocortical carcinoma, Congress, ACC, American Society of Clinical Oncology, Patient, Vaccine, Pharmaceutical industry, Villejuif

These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2022

Key Points: 
  • These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2022
    EO2401 combines OncoMimics peptides which are known driver antigens present on aggressive solid tumors.
  • Enterome selected these peptides using its Mimicry platform, applying best-in-class biocomputational tools and bioassays to identify novel therapeutics from its proprietary database of 20+ million bioactive gut microbiome peptides and proteins.
  • The results of the second part of the study will be presented at ESMO Congress.
  • An update on the ongoing expanded study for treatment of patients with MPP will be presented at ESMO Congress.

Enterome to present updates on EO2401, its first-in-class OncoMimics™ therapeutic cancer vaccine targeting solid tumors, at ESMO Congress 2022

Retrieved on: 
Tuesday, September 6, 2022
European Society for Medical Oncology, Glioblastoma, Protein, Associate, Bevacizumab, Peptide, Society, Nivolumab, ESMO, Gustave Roussy, Assay, Antigen, Annual general meeting, Therapy, ASCO, Oncology, MPP, CEST, Adrenocortical carcinoma, Congress, ACC, American Society of Clinical Oncology, Patient, Vaccine, Pharmaceutical industry, Villejuif

These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2022

Key Points: 
  • These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2022
    EO2401 combines OncoMimics peptides which are known driver antigens present on aggressive solid tumors.
  • Enterome selected these peptides using its Mimicry platform, applying best-in-class biocomputational tools and bioassays to identify novel therapeutics from its proprietary database of 20+ million bioactive gut microbiome peptides and proteins.
  • The results of the second part of the study will be presented at ESMO Congress.
  • An update on the ongoing expanded study for treatment of patients with MPP will be presented at ESMO Congress.

Roche's VENTANA PD-L1 (SP263) test gains CE label expansion as a companion diagnostic to identify non-small cell lung cancer patients eligible for Tecentriq

Retrieved on: 
Wednesday, August 24, 2022
Lung cancer, Mortality, Lung, Dow Jones, Cancer, Neoplasm, Medication, Large-cell lung carcinoma, Internet, Disease, Death, Recurrence, Incidence, Hoffmann-La Roche, Genentech, Assay, Treatment of lung cancer, Multimedia, RO, Prevalence, Immunotherapy, NSCLC, Pharma, Biomarker, Roche Diagnostics, ROG, Risk, European Commission, CE, PD-L1, Benchmark, Trial of the century, Patient, World Health Organization, Pharmaceutical industry, Medical imaging, Palladium, Fine chemical, Medical device, Atezolizumab, Diagnosis, Chugai Pharmaceutical Co.

TUCSON, Ariz, Aug. 24, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced CE label expansion of the VENTANA PD-L1 (SP263) Assay in non-small cell lung cancer (NSCLC) as a companion diagnostic for Tecentriq (atezolizumab).

Key Points: 
  • TUCSON, Ariz, Aug. 24, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced CE label expansion of the VENTANA PD-L1 (SP263) Assay in non-small cell lung cancer (NSCLC) as a companion diagnostic for Tecentriq (atezolizumab).
  • The current standard of care for patients with early stage lung cancer is removal of the tumour, which may be followed by chemotherapy.
  • "We are proud to offer a PD-L1 test that may qualify lung cancer patients for Tecentriq therapy.
  • VENTANA PD-L1 (SP263) Assay is used to detect programmed death ligand-1 (PD-L1) protein in non-small cell lung carcinoma (NSCLC) patients.

Roche's VENTANA PD-L1 (SP263) test gains CE label expansion as a companion diagnostic to identify non-small cell lung cancer patients eligible for Tecentriq

Retrieved on: 
Wednesday, August 24, 2022
Lung cancer, Mortality, Lung, Dow Jones, Cancer, Neoplasm, Medication, Large-cell lung carcinoma, Internet, Disease, Death, Recurrence, Incidence, Hoffmann-La Roche, Genentech, Assay, Treatment of lung cancer, RO, Prevalence, Immunotherapy, NSCLC, Pharma, Biomarker, Roche Diagnostics, ROG, Risk, European Commission, CE, PD-L1, Benchmark, Trial of the century, Patient, World Health Organization, Pharmaceutical industry, Medical imaging, Palladium, Fine chemical, Medical device, Atezolizumab, Diagnosis, Chugai Pharmaceutical Co.

TUCSON, Ariz., Aug. 24, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced CE label expansion of the VENTANA PD-L1 (SP263) Assay in non-small cell lung cancer (NSCLC) as a companion diagnostic for Tecentriq (atezolizumab).

Key Points: 
  • TUCSON, Ariz., Aug. 24, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced CE label expansion of the VENTANA PD-L1 (SP263) Assay in non-small cell lung cancer (NSCLC) as a companion diagnostic for Tecentriq (atezolizumab).
  • The current standard of care for patients with early stage lung cancer is removal of the tumour, which may be followed by chemotherapy.
  • "We are proud to offer a PD-L1 test that may qualify lung cancer patients for Tecentriq therapy.
  • VENTANA PD-L1 (SP263) Assay is used to detect programmed death ligand-1 (PD-L1) protein in non-small cell lung carcinoma (NSCLC) patients.

Twist Bioscience and Biotia Receive Expanded Emergency Use Authorization to Report Genetic Variants of SARS-CoV-2

Retrieved on: 
Tuesday, August 2, 2022
Infectious Diseases, Biotechnology, Genetics, Health, Regulation of tobacco by the U.S. Food and Drug Administration, DNA, NGS, CLIA, Severe acute respiratory syndrome coronavirus 2, Twist Bioscience, Genomics, Security (finance), Genome, Laboratory, Food, U.S. Securities and Exchange Commission, Polymerase chain reaction, Marker beacon, Health, CEO, SEC, Silicon, Martek Biosciences Corporation, Research, Agriculture, Delta, Drug discovery, Private Securities Litigation Reform Act, Bronchoalveolar lavage, Infection, Risk, COVID-19, Multimedia, Public health, NASDAQ, FASTQ, Microbiology Spectrum, BAL, EUA, Technology, FDA, COVID-19 testing, RUO, COVID, NP, Assay, Cornell Tech, Doctor of Philosophy, Therapy, Biology, Engineering, PCR, Clinical Laboratory, Synthetic biology, Illumina, Emergency Use Authorization, RNA, Vaccine, Pharmaceutical industry, Omicron

With the expanded authorization, the reporting of the identified and differentiated SARS-CoV-2 genetic mutations and viral lineages (e.g.

Key Points: 
  • With the expanded authorization, the reporting of the identified and differentiated SARS-CoV-2 genetic mutations and viral lineages (e.g.
  • The authorization also allows for the reporting of individual mutations in patient samples, information that is important to track as the virus evolves and new variants emerge.
  • This expanded FDA authorization marks an important step forward, enabling improved COVID-19 patient care, commented Niamh OHara, Ph.D., CEO and co-founder of Biotia.
  • Twist and Biotia also offer a research use only (RUO) version of the SARS-CoV-2 NGS Assay, for non-clinical labs.

LifeNet Health LifeSciences launches new, human-relevant Cell-Based Assay Service for drug and compound discovery

Retrieved on: 
Monday, August 1, 2022
Acquisition, DMPK, View, MPS, Industry, Tissue, Doctor of Philosophy, Research, ADME, Solution, Toxicology, Health, Safety, Multimedia, Cytotoxicity, Biocompatibility, Organization, Biotechnology, MD, Assay, Biology, Face, Pharmaceutical industry, Medical device, Mobile phone

VIRGINIA BEACH, Va., Aug. 1, 2022 /PRNewswire/ -- LifeNet Health LifeSciences, a leader in all-human biomedical research solutions, is launching a new Cell-Based Assay Service following the acquisition of biotechnology firm IONTOX. These new in vitro screening options offer alternatives to animal testing that support safer, more effective novel compound discovery – providing a new level of human relevance and predictability, while furthering LifeNet Health's commitment to improve lives through the gift of donation.

Key Points: 
  • VIRGINIA BEACH, Va., Aug. 1, 2022 /PRNewswire/ -- LifeNet Health LifeSciences , a leader in all-human biomedical research solutions, is launching a new Cell-Based Assay Service following the acquisition of biotechnology firm IONTOX.
  • The new services from LifeNet Health LifeSciencesinclude:
    Cytotoxicity screening using high-quality, cell-based models with strong human relevance to identify potential adverse effects from drugs or chemicals.
  • To support this expansion, LifeNet Health LifeSciences welcomes IONTOX and its team of scientists including founder and industry leader James McKim, PhD to the LifeNet Health LifeSciences division.
  • LifeNet Health LifeSciences has grown into a leading provider of all-human cells and biospecimens for research.